Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
99%
Lymphoma
86%
Mycobacterium Tuberculosis (M. tb)
80%
Follicular Lymphoma
61%
Overall Survival
60%
Immunochemotherapy
56%
Tuberculosis
56%
Active Tuberculosis
48%
Chemotherapy
47%
Progression-free Survival
45%
Epstein-Barr Virus
44%
Lung
38%
Pulmonary Granulomas
33%
Murine Model
33%
Chronic Lymphocytic Leukemia
32%
Prognostic Significance
32%
Necrosis
32%
C57BL
30%
Aggressive B-cell Lymphoma
29%
Aerosol
29%
High-grade B-cell Lymphoma
28%
Tumor
28%
Bacillary Load
27%
In Vivo murine Model
27%
Combined Antiretroviral Therapy (cART)
27%
Lymphoma Patients
27%
Hodgkin Lymphoma
26%
De Novo Diffuse Large B-cell Lymphoma
25%
Cervical mucus
25%
Neoadjuvant Chemotherapy
25%
Siglec
25%
MYC Protein
25%
Plasmablastic Lymphoma
25%
Granuloma
24%
Protein Expression
24%
Prognostic Impact
23%
People Living with HIV (PLHIV)
23%
Burkitt
23%
HIV Infection
22%
Foamy Macrophages
22%
Time to Progression
22%
Mycobacterium Tuberculosis Infection
22%
B-cell Lymphoma 2 (Bcl-2)
21%
Mouse Strain
21%
Improved Survival
20%
Macrophages
20%
AIDS/HIV
20%
MYC Translocation
19%
Flow Cytometry
19%
Th1-Th2
19%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Human Immunodeficiency Virus
90%
Neoplasm
55%
Epstein Barr Virus
48%
B-Cell Lymphoma
46%
Tuberculosis
40%
B Cell
39%
Follicular Lymphoma
36%
Non-Hodgkin Lymphoma
34%
Chemotherapy
34%
B-Cell Chronic Lymphocytic Leukemia
33%
Diseases
33%
Diagnosis
31%
Overall Survival
31%
Biological Marker
29%
Progression Free Survival
28%
Breast Cancer
27%
Hodgkin's Lymphoma
26%
Protein Expression
25%
Neoadjuvant Chemotherapy
25%
Sialoadhesin
25%
Lymphocyte
25%
Plasmablastic Lymphoma
25%
Burkitt's Lymphoma
22%
Rituximab
19%
Immunoglobulin
19%
Mycobacterium Tuberculosis
19%
Lymphoproliferative Disease
19%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
19%
Differential Diagnosis
17%
MALT Lymphoma
17%
Prognostic Factor
17%
Antiretroviral Therapy
17%
Low Drug Dose
17%
Flow Cytometry
17%
Lung
17%
Immunohistochemistry
15%
Infection
15%
Messenger RNA
14%
Necrosis
12%
Lung Granuloma
12%
Monoclonal B Cell Lymphocytosis
12%
Upper Urinary Tract
12%
BRCA1
12%
Lung Adenocarcinoma
12%
Triple Negative Breast Cancer
12%
Histiocytosis
12%
Beta 2 Microglobulin
12%
Acetylsalicylic Acid
12%
Wedge Resection
12%
Immunology and Microbiology
Mycobacterium Tuberculosis
85%
B Cell
62%
Granuloma
53%
Human Immunodeficiency Virus
42%
Overall Survival
39%
Progression Free Survival
37%
Macrophage
34%
Low Drug Dose
32%
C3HeB/Fe Mouse
25%
Uterine Cervix Mucosa
25%
Sialoadhesin
25%
Epstein Barr Virus
25%
C57BL 6 Mouse
21%
Human Immunodeficiency Virus Infection
19%
Cytokine
18%
Tumor Necrosis Factor
18%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
18%
Immunity
17%
Interleukin 6
16%
Mycobacteria
16%
Rituximab
16%
Human Immunodeficiency Virus 1
16%
Bacterial Load
16%
Neutrophil Granulocyte
15%
Protein Expression
15%
T Cell
14%
Mouse Strain
13%
Lymphocyte
13%
Minipig
12%
Glycosyltransferase
12%
Regulatory T Cell
12%
Glycan
12%
Innate Immune System
12%
Colony Forming Unit S
12%
Disease Free Survival
12%
Memory T Cell
12%
Intestine Flora
12%
Lymphoproliferative Disorders
12%
DBA 2 Mouse
12%
Dendritic Cell
12%
Immunotherapy
12%
Inflammation Response
12%
Intravenous Immunoglobulin
12%
Gene Mutation
12%
Interferon Regulatory Factor 4
12%
Cancer Immunotherapy
12%
CD4
10%
Immune Response
10%
Interleukin 10
10%
Neutrophil
10%
